Budapest Post

Cum Deo pro Patria et Libertate
Budapest, Europe and world news

Weight loss drug semaglutide approved for NHS use

Weight loss drug semaglutide approved for NHS use

A weight loss jab that has gained popularity in the US has been approved for use by the NHS in England.

The National Institute for Health and Care Excellence (NICE) concluded semaglutide, marketed as Wegovy, is safe, effective and affordable.

Delivered via an injection into the skin, the drug makes people feel fuller and more satisfied, so they eat less.

Famous personalities such as Elon Musk claim to have used it - with a "craze" allegedly developing in Hollywood.


Lifestyle changes


Based on evidence from clinical trials, NICE says semaglutide could help people reduce their weight by over 10%, if implemented alongside nutrition and lifestyle changes.

It will be recommended for use by people with at least one weight-related health condition, as well as those who have a body mass index (BMI) which puts them near the top of the obese range.

BMI is calculated by dividing an adult's weight in kilograms by the square of their height in metres.

Those who are lower on the obese BMI range - a BMI between 30 and 34.9kg/m2 - could also be offered the drug if they have a weight-related health condition. NICE lists these as someone who is pre-diabetic, has type 2 diabetes, high blood pressure, heart disease or obstructive sleep apnoea.

Once-weekly injections of Wegovy will have to be prescribed by a specialist, and an individual will only be able to take the drug for a maximum of two years.

Semaglutide is also found in the diabetes medicine Ozempic, but, unlike Ozempic - which is intended for those with type 2 diabetes - Wegovy is recommended specifically for weight loss.

The drug works as an appetite suppressant by mimicking a hormone called Glucagon-like peptide-1 (GLP-1). This intestinal hormone is released after eating and typically makes people feel fuller, so should help reduce overall calorie intake.

Kailey Wood runs a TikTok account sharing her weight loss journey


An article published last year in Variety suggested the diabetes medicine Ozempic, which contains semaglutide, is being used by some professionals in the film and entertainment industry to lose weight quickly.

It has become so popular that there are currently widespread shortages in the US and concerns for those people who rely on the drug for medical reasons.

Insurance companies in the US are refusing to cover its use among people who are not diabetic and not taking it as a prescribed medicine.


'Ozempic face'


Pharmaceutical company Novo Nordisk, which makes both Ozempic and Wegovy, says the products should only be used as recommended by a doctor.

Like all medication, semaglutide comes with side-effects and risks - including nausea, stomach pain, vomiting and diarrhoea.

In addition, rapid weight loss can also lead to the skin losing collagen and elastin, causing what Vogue Magazine has dubbed the gaunt "Ozempic face".

Kailey Wood, 36, has been taking Ozempic for seven months, after being prescribed the drug by her doctor in New York.

She tells the BBC that she has lost just under 30kg - going from obese to healthy in the BMI range.

Semaglutide injections will be approved under NICE guidance


"I have Polycystic Ovarian Syndrome (PCOS) and insulin resistance, but honestly I didn't really struggle with my weight until I hit my 30s - after I had my kids," she says.

"I was rapidly gaining weight. I had a personal trainer and was on every diet known to man - keto, low carbohydrate, intermittent fasting and nothing seemed to work,".

When Kailey went for tests with her doctor, she was told she had high blood pressure and high cholesterol and, due to the risks associated with PCOS, she was at risk of developing type 2 diabetes too.

"The long-term effects [of being obese] freaked me out having two daughters," she says.

"I just wanted to get to my best self - to show them what a healthy mum looks like; to get outside and play with them."

Kailey, who works for a tech start-up and runs her own TikTok page, says that people who want to use semaglutide need to know the drug does have side-effects.

"When you start taking this medication, your body almost goes into shock - you get headaches, nausea, tiredness," she explains.

"But your body starts to get used to it. You have to be mindful and listen to your body."

Kailey says those elements of the US media who promoting the drug as a "get skinny quick product" leave "a bad taste". She believes it sends the wrong message.

"What it's really doing is changing people's lives - treating the patient before they have the disease," she says.

Just over a quarter of adults in England are obese and around a third are overweight, according to official figures.

In the UK, obesity is thought to cost the NHS £6.1bn per year, government estimates show.

The drug semaglutide is currently under consultation in Scotland, with Wales expected to follow the NICE guidelines issued in England.

Helen Knight, director of medicines evaluation at NICE, said: "For some people losing weight is a real challenge, which is why a medicine like semaglutide is a welcome option.

"It won't be available to everyone. Our committee has made specific recommendations to ensure it remains value for money for the taxpayer."

Dr Duane Mellor, registered dietitian and senior lecturer at Aston Medical School, Aston University, said: "It is important to remember that living with a higher body weight or obesity is not a lifestyle choice, and people wanting to improve their health should be supported to do that.

"It is also clear that semaglutide is not intended to be a lifestyle weight-loss product in the UK. It is to be used for the purpose of improving health."

Anyone who is offered semaglutide on the NHS will be supported by specialist weight management services, including support from a dietitian.

AI Disclaimer: An advanced artificial intelligence (AI) system generated the content of this page on its own. This innovative technology conducts extensive research from a variety of reliable sources, performs rigorous fact-checking and verification, cleans up and balances biased or manipulated content, and presents a minimal factual summary that is just enough yet essential for you to function as an informed and educated citizen. Please keep in mind, however, that this system is an evolving technology, and as a result, the article may contain accidental inaccuracies or errors. We urge you to help us improve our site by reporting any inaccuracies you find using the "Contact Us" link at the bottom of this page. Your helpful feedback helps us improve our system and deliver more precise content. When you find an article of interest here, please look for the full and extensive coverage of this topic in traditional news sources, as they are written by professional journalists that we try to support, not replace. We appreciate your understanding and assistance.
Newsletter

Related Articles

0:00
0:00
Close
White House Eyes Budapest for Peace Talks
Cave Diving Beneath the Streets of Budapest
Another American Restaurant Chain Opens in Budapest
Hungarian Opposition Politician Supports Ukrainian Commander
U.S. Celebrates Labor Day
Hungarian National Team Captain Scores Epic Goal
Opposition Leader Threatens Media Outlets
Budapest Central European Fashion Week Kicks Off
American Airlines Adds New Flights to Budapest
F1 Hungarian Grand Prix Wraps Up
WhatsApp is rolling out a feature that looks a lot like Telegram.
U.S. Trade Representative says Washington still negotiating trade deals after court rules tariffs illegal
Von der Leyen says Europe drawing up 'precise' plans to send troops to Ukraine
Kremlin accuses Europe of hindering Trump’s peace efforts in Ukraine
German Chancellor Merz expects Ukraine war to last a long time
Why Hungarians feel poorer than their neighbours despite rising wages
Fidesz minister vows Hungary will ‘rescue’ a crisis-stricken EU
Budapest completes back-to-school infrastructure upgrade
Hungarian–Chinese consortium wins tender for Budapest trolleybuses
Betting market fuels speculation about Viktor Orbán’s future
European Union Plans for Ukraine Deployment
ECB Warns Against Inflation Complacency
Concerns Over North Cyprus Casino Development
Shipping Companies Look Beyond Chinese Finance
Rural Exodus Fueling European Wildfires
China Hosts Major Security Meeting
Germany Marks a Decade Since Migrant Wave with Divisions, Success Stories, and Political Shifts
Liverpool Defeat Arsenal 1–0 with Szoboszlai Free-Kick to Stay Top of Premier League
Chinese Stock Market Rally Fueled by Domestic Investors
Israeli Airstrike in Yemen Kills Houthi Prime Minister
Ukrainian Nationalist Politician Andriy Parubiy Assassinated in Lviv
Trump Administration Seeks to Repurpose $4.9 Billion in Foreign Aid
Corporate America Cuts Middle Management as Bosses Take On Triple the Workload
Parents Sue OpenAI After Teen’s Death, Alleging ChatGPT Encouraged Suicide
Amazon Faces Lawsuit Over 'Buy' Label on Digital Streaming Content
US Appeals Court Rules Against Most Trump-Era Tariffs
Germany’s Auto Industry Sheds 51,500 Jobs in First Half of 2025 Amid Deepening Crisis
Bruce Willis Relocated Due to Advanced Dementia
French and Korean Nuclear Majors Clash As EU Launches Foreign Subsidy Probe
EU Stands Firm on Digital Rules as Trump Warns of Retaliation
Getting Ready for the 3rd Time in Its History, Germany Approves Voluntary Military Service for Teenagers
Denmark Confronts U.S. Diplomat Over Covert Trump-Linked Influence in Greenland
Trump Demands RICO Charges Against George Soros and Son for Funding Violent Protests
Taylor Swift Announces Engagement to NFL Star Travis Kelce
France May Need IMF Bailout, Warns Finance Minister
After the Shock of Defeat, Iranians Yearn for Change
Ukraine Finally Allows Young Men Aged Eighteen to Twenty-Two to Leave the Country
The Porn Remains, Privacy Disappears: How Britain Broke the Internet in Ten Days
YouTube Altered Content by Artificial Intelligence – Without Permission
Ukrainian Refugee Iryna Zarutska Fled War To US, Stabbed To Death
×